TransCode Therapeutics, Inc. (RNAZ)
NASDAQ: RNAZ · Real-Time Price · USD
8.70
-0.21 (-2.36%)
At close: Apr 16, 2026, 4:00 PM EDT
8.87
+0.17 (1.95%)
After-hours: Apr 16, 2026, 4:56 PM EDT

TransCode Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
14.565.957.158.43.4
Research & Development
13.429.7112.2610.232.75
Total Operating Expenses
27.9815.6619.4218.636.15
Operating Income
-27.98-15.66-19.42-18.63-6.15
Interest Income
0.0800.010.020
Interest Expense
-0.01-0.03-0.06-0.03-0.1
Other Non-Operating Income (Expense)
-6.53-1.070.921.08-0.6
Total Non-Operating Income (Expense)
-6.45-1.090.871.07-0.69
Pretax Income
-34.44-16.76-18.55-17.57-6.84
Provision for Income Taxes
-0.23----
Net Income
-36.27-16.79-18.55-17.57-6.84
Net Income Attributable to Preferred Dividends
1.610.03---
Net Income to Common
-36.27-16.79-18.55-17.57-6.84
Shares Outstanding (Basic)
10000
Shares Outstanding (Diluted)
10000
Shares Change (YoY)
5392.22%6382.75%1003.39%-179.92%
EPS (Basic)
-52.59-1336.63-95732.30-1000500.00-748.44
EPS (Diluted)
-52.59-1336.63-95732.30-1000500.00-748.44
Shares Outstanding
0.920.04000
Free Cash Flow
-19.52-13.36-18.11-15.86-5.52
Free Cash Flow Per Share
-28.31-1063.68-93488.90-903576.00-314515.00
EBITDA
-27.87-15.13-18.9-18.54-6.11
EBIT
-27.98-15.66-19.42-18.63-6.15
Effective Tax Rate
0.66%0.00%0.00%0.00%0.00%
Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q